Status:
COMPLETED
Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18-100 years
Brief Summary
The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
Eligibility Criteria
Inclusion
- Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav
- Greater than 18 years old
- Diagnosed with glaucoma or ocular hypertension
- Registered at the primary care practice for \> 12 months
Exclusion
- None
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
2015 Patients enrolled
Trial Details
Trial ID
NCT01206361
Start Date
February 1 2010
End Date
August 1 2010
Last Update
February 2 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.